Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

Core Insights - Roche's investigational candidate giredestrant, in combination with palbociclib, did not meet its primary endpoint in the phase III persevERA study for ER-positive, HER2-negative breast cancer [2][3][8] - Despite missing the primary endpoint, the combination showed a numerical improvement in progression-free survival (PFS) [3][8] - The safety profile of the giredestrant and palbociclib combination was consistent with expectations and manageable [4][8] Study Results - The phase III persevERA study involved 992 patients and compared giredestrant plus palbociclib against letrozole plus palbociclib [2] - The study failed to achieve a statistically significant improvement in PFS in the intent-to-treat population [3] - Management remains optimistic about giredestrant's long-term potential and plans to explore its use with CDK4/6 inhibitors in future studies [5] Regulatory Developments - Roche's new drug application (NDA) for giredestrant in combination with everolimus is under FDA review, with a target action date set for December 18, 2026 [6][8] - If approved, this regimen could be the first oral SERD combination available in the post-CDK4/6 inhibitor setting [7] Clinical Development - Giredestrant is part of a broader clinical program with five phase III studies across various treatment settings [14] - The evERA study showed significant PFS improvement compared to standard therapy, marking the first positive phase III outcome for giredestrant [10][11] - The second phase III study, pionERA, is expected to report results in 2027 [12] Market Performance - Roche's shares have increased by 32.4% over the past six months, outperforming the industry growth of 20% [7]